ArticleJournal of reproduction & infertility
A New Strategy for Chronic Endometritis Treatment Using Fermented Soy Product (ImmuBalance
Article in Journal of reproduction & infertility. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic endometritis (CE) significantly contributes to repeated implantation failure (RIF). Although antibiotics are common treatments for CE, some patients do not achieve resolution. Therefore, the use of an alternative method involving the administration of ImmuBalance Methods: This retrospective study was conducted between April 2021 and August 2022. A total of 819 women with CE were treated with antibiotics-1 (doxycycline, n=809) or IMB (n=10, Group 1). Following endometrial biopsies, CE was not resolved in 209 out of 819 women. Subsequently, 194 patients were treated with antibiotics-1 (n=4) or -2 (amoxicillin, azithromycin, and metronidazole, n=190), whereas 15 were treated with IMB (n=15, Group 2). After the treatment with antibiotics-2, four women underwent IMB (Group 3). Statistical analysis of the number of plasma cells with CD138 before and after treatment was conducted using Fisher's exact test and p-values <0.05 were considered statistically significant. Results: CE was treated in 60% of patients (6/10) in Group 1; however, the reduction in CD138 count was not statistically significant (p=0.13). In Groups 2 and 3, CE was treated with a significantly reduced CD138 count (Group 2, p<0.01; Group 3, p=0.04). CE was treated in 100% of cases in Group 2 and 3 (15/15 and 4/4, respectively). Conclusion: Based on the findings of this study, administration of IMB may be effective in treating CE, especially following antibiotic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.